Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT capsules versus empty capsules plus conventional therapy for minimal hepatic encephalopathy
ChiCTR2400091613Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Oct 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of allogeneic fecal microbiota in hepatic encephalopathy (HE) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Psychometric hepatic encephalopathy score, Microbiological analysis of feces and 4 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on ChiCTR2400091613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091613.